Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.66 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20390644 | 0.80 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1HSD17B1 | |
| SCHEMBL11332250 | 0.80 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL9852272 | 0.80 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL16238754 | 0.80 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL20390138 | 0.80 | ADORA3 (0.66) | ADORA3ADORA2AADORA2BADORA1HSD17B1 | |
| SCHEMBL69810 | 0.79 | ADORA3 (1.00) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL1180545 | 0.78 | HSD17B1 (0.72) | ADORA3ADORA2AADORA2BADORA1HSD17B1 | |
| SCHEMBL3252621 | 0.78 | ADORA3 (0.68) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL13659745 | 0.76 | ADORA3 (0.59) | ADORA3ADORA2AADORA2BADORA1CYP19A1 | |
| SCHEMBL13822161 | 0.76 | ADORA3 (0.59) | ADORA3ADORA2AADORA2BADORA1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010077836-A2 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ADORA3 215/4885ADORA2A 123/4885ADORA2B 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.